Shots:

• ImaginAb to receive license fees and other contingent payments and will partner with Neuvogen to implement clinical doses of 89Zr CD8 Immuno-PET imaging agents in their clinical trials of therapeutic vaccines
• ImaginAb will provide technical- clinical & regulatory support to Neuvogen. ImaginAb's PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients
• The agreement gives Neuvogen access to highly specific and precise imaging of the presence of CD8 T Cells in solid tumors

 ­ Ref: PRNewswire | Image: ImaginAb